Check-Cap targets Q3 2026 for MBody AI business combination
Check-Cap Ltd. expects to complete its merger with MBody AI Corp. in Q3 2026, narrowing a prior H2 2026 estimate after resolving SEC comments. Final Nasdaq approval and other conditions remain pending.

*this image is generated using AI for illustrative purposes only.
Check-Cap Ltd. (NASDAQ: MBAI) has updated the expected closing timeline for its proposed business combination with MBody AI Corp., projecting completion in the third quarter of 2026. This update narrows the company’s previously announced expectation of a closing in the second half of 2026, providing greater certainty to investors regarding the transaction’s execution schedule. The accelerated timeline follows Check-Cap’s response to all comments received from the U.S. Securities and Exchange Commission (SEC) staff regarding its registration statement.
The transaction remains subject to final approval by Nasdaq and the satisfaction of remaining customary closing conditions, none of which can be assured at this stage. Check-Cap publicly filed its registration statement on Form F-1 with the SEC on July 24, 2026. The company confirmed that it has addressed all regulatory inquiries from the SEC staff, clearing a key procedural hurdle in the merger process.
Transaction Status
The business combination involves Check-Cap Ltd. and MBody AI Corp. The revised timeline reflects progress in regulatory compliance but does not guarantee closure. Key milestones and conditions include:
| Milestone | Status / Date |
|---|---|
| Form F-1 Filing | July 24, 2026 |
| SEC Comments | Responded to all |
| Nasdaq Approval | Pending |
| Expected Closing | Q3 2026 |
Investors should note that while the SEC comment period is resolved, final regulatory approvals and customary closing conditions must still be met. The shift from a broad second-half window to a specific quarter suggests internal confidence in meeting these conditions by mid-2026.
What the Numbers Show
The narrowing of the closing window from six months (H2 2026) to three months (Q3 2026) indicates that the primary delay factor—regulatory review—has been largely resolved. However, the explicit disclaimer that closing conditions "cannot be assured" highlights residual execution risk. For shareholders, the Q3 target provides a clearer horizon for potential liquidity events or operational integration, though no financial metrics were disclosed in this update to assess valuation impact.
What specific customary closing conditions remain outstanding, and what is the likelihood of Nasdaq approval delaying the Q3 2026 target?
How might the accelerated timeline impact MBody AI's valuation or investor sentiment compared to the previous H2 2026 window?
Are there any pending regulatory hurdles in jurisdictions other than the U.S. that could still jeopardize the merger completion?



























